Abstract
Peptidylglycine alpha-amidating monooxygenase (PAM), the enzyme responsible for the alpha-amidation of neuroendocrine peptides, is more prevalent in the atrium of the heart than in pituitary or brain. RNase protection assays indicate that PAM transcripts account for approximately 0.5% of the mRNA in the neonatal atrium and 0.06% of the mRNA in the neonatal ventricle. In primary atrial cardiomyocyte cultures PAM mRNA turns over slowly, with a half-life of approximately 20 h. Levels of PAM mRNA in primary atrial cardiomyocytes are increased to 16.5% of control upon treatment with dexamethasone and decreased to 63% of control upon treatment with thyroid hormone.
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Animals, Newborn
-
Antisense Elements (Genetics)
-
Brain / enzymology
-
Cells, Cultured
-
Dexamethasone / pharmacology
-
Gene Expression Regulation, Enzymologic* / drug effects
-
Heart Atria
-
Heart Ventricles
-
Kinetics
-
Mixed Function Oxygenases / biosynthesis*
-
Multienzyme Complexes*
-
Myocardium / enzymology*
-
Organ Specificity
-
Pituitary Gland / enzymology
-
RNA, Messenger / biosynthesis
-
RNA, Messenger / metabolism*
-
Rats
-
Rats, Sprague-Dawley
-
Transcription, Genetic
-
Triiodothyronine / pharmacology
Substances
-
Antisense Elements (Genetics)
-
Multienzyme Complexes
-
RNA, Messenger
-
Triiodothyronine
-
Dexamethasone
-
Mixed Function Oxygenases
-
peptidylglycine monooxygenase